Lon Juricic Highlights the Following Stocks: IOMED, Seattle Genetics, ArQule, Incyte, OSI Pharma, and Genentech.

Business Editors

CHICAGO--(BUSINESS WIRE)--Oct. 10, 2003

The biotech industry has been feeling a little under the weather over the past few weeks, but Lon Juricic has the remedy for sickly investors with updates on four stocks in his portfolio. Learn about IOMED, Inc. (AMEX:IOX), Seattle Genetics, Inc. (NASDAQ:SGEN), ArQule, Inc. (NASDAQ:ARQL), Incyte Corporation (NASDAQ:INCY), OSI Pharmaceuticals (NASDAQ:OSIP), and Genentech (NYSE:DNA). Click here for the full story exclusively on Zacks.com: http://featuredexpert2bw.zacks.com/

Here are the highlights from the Featured Expert column:

IOMED, Inc. (AMEX:IOX) is engaged in the development, manufacture and sale of active drug transport systems primarily used to treat acute local inflammation in the sports and occupational medicine and physical therapy markets. On September 3rd, IOMED, Inc. reported financial results for its fourth quarter and fiscal year ended June 30, 2003. For the fourth quarter and fiscal year, IOMED reported net income of $0.04 and $0.10 per diluted share, respectively, on record product sales. When Lon Juricic first recommended IOX in the Sept 3 issue, he told members that he'd found another biotech gem. Others saw the same thing. The stock has surged since his recommendation. Although the market cap on IOX has increased from $10 million to $16 million, since the first recommendation, Juricic still believes there is more room to run.

Seattle Genetics, Inc. (NASDAQ:SGEN) discovers and develops monoclonal antibody-based drugs to treat cancer and other human diseases. The Company's product candidates encompass three technologies: genetically engineered monoclonal antibodies, monoclonal antibody-drug conjugates (ADCs) and antibody-directed enzyme prodrug therapy (ADEPT). The momentum just keeps building and the positive news on SGEN's cancer treatments has Juricic excited to see the trial results. In the past, he's cautioned that the stock looked a bit frothy on the chart, but recent consolidation in the $6 range has cleaned up a lot of the slack as weak hands have been exiting.

ArQule, Inc. (NASDAQ:ARQL), is a recognized leader in small-molecule chemistry, and is pursuing a strategy to become an efficient drug discovery and development company. On Oct. 1st the company said CFO David C. Hastings left the company to take the CFO position at Incyte Corporation (NASDAQ:INCY). On the positive side of things, the initiation of the first human clinical trial with CO-501, a novel investigational small-molecule anti-cancer drug. CO-501 is intended to selectively kill cancer cells and spare normal cells by restoring and activating cellular checkpoints known to be defective in cancer.

OSI Pharmaceuticals (NASDAQ:OSIP) is a leading biotechnology company focused on the discovery, development and commercialization of high-quality, next-generation oncology products that both extend and improve the quality-of-life for cancer patients worldwide. On October 1st, Genentech (NYSE:DNA), OSI Pharmaceuticals, and Roche announced that two first-line Phase III studies (called TRIBUTE in the U.S. and TALENT outside of the U.S.) of Tarceva plus standard chemotherapy in metastatic non-small cell lung cancer did not meet their primary endpoints of improving overall survival. While disappointing the results were not unexpected. One thing the results do bring is relief to the recent overhang in the stock.

Get Lon Juricic's specific recommendations on the above-mentioned companies, and make sure to look at more of his updated positions and a new recommendation by clicking: http://featuredexpert3bw.zacks.com/

About Zacks Featured Experts

To be a successful investor you need professional advice. Experts who know what they're talking about and can help you achieve your financial goals in good markets...and especially in bad ones will help you improve your portfolio. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters to you on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc.

Recommendations from Featured Experts Highlighted in FREE Investment Newsletter

The best way to tap into the powerful advice from these experts is through our free weekly e-mail newsletter, "Profit from the Pros". Each week we highlight several Featured Experts in this free e-mail newsletter. Get your free subscription to "Profit from the Pros" at: http://www.freeprofit1bw.zacks.com

About Zacks

Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind our work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. Our goal is to unlock their profitable insights for our customers. And there is no better way to enjoy this investment success, than with a FREE subscription to "Profit from the Pros" weekly e-mail newsletter. For your free newsletter, visit http://www.freeprofitbw.zacks.com

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.